Fox Chase Cancer Center to Participate in PurpleStride Philadelphia 2019

PHILADELPHIA (October 11, 2019) — Fox Chase Cancer Center is proud to support the Pancreatic Cancer Action Network (PanCAN) for PurpleStride Philadelphia 2019. Fox Chase will walk alongside pancreatic cancer survivors, their loved ones, caregivers, and researchers on Saturday, November 2 to raise money for pancreatic cancer research and patient services.

The event is being held at Memorial Hall, Fairmount Park, 43 South Concourse Street. Opening ceremonies start at 7:15 a.m. and the 5K run/walk begins at 8:00 a.m.

Paul Campbell, PhD, assistant professor in the Cancer Biology Program at Fox Chase, is this year’s team leader and an honorary event co-chair.  The clinicians, researchers, and staff on the Fox Chase team are affiliated with the center’s Marvin and Concetta Greenberg Pancreatic Cancer Institute, which was founded in 2017.

“PurpleStride gives those of us who are researchers the opportunity to interact with the global pancreatic cancer community as a whole,” Campbell said. “There are survivors, family members, and caregivers who have been affected by the disease. It brings together all these groups to celebrate successes and move toward better research, government advocacy, and most importantly, improved patient care.”

PurpleStride is PanCAN’s signature walk program, which raised approximately $14.9 million just in 2018. This year, more than 55 PurpleStride events will take place cross the country, which will aid in PanCAN’s mission to advance research and create hope for families facing this deadly disease. Although the five-year survival rate for pancreatic cancer was six percent in 2014, it has steadily increased to nine percent today – much due to the grassroots efforts by advocacy groups like PanCAN and the partnerships it builds within the health community.  

For more information about Philadelphia PurpleStride 2019, to join the Fox Chase team, or to make a donation visit www.purplestride.org/philadelphia.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427